Ophthal Medical News about macular oedema

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion
Eye, 10/06/09

Cheng KC et al. – These short–term results indicate that intravitreal injection of triamcinolone acetonide or bevacizumab can both improve visual acuity and decrease macular oedema temporarily in eyes with BRVO. However, the therapeutic effects of intravitreal triamcinolone acetonide showed no significant differences compared with intravitreal bevacizumab with regard to anatomical and functional outcomes but seemed to cause more adverse events than bevacizumab.

Exclusive Author Commentary
K-C Cheng, 11/09/09

1.Intravitreal injection of triamcinolone acetonide or bevacizumab is effective in reversing macular edema and improving visual acuity in branch retinal vein occlusion but the effects is not permanent and re-treatment may be necessary in some patients. 2.One major side effect after intravitreal triamcinolone acetonide is an increase in intraocular pressure. 3.It did not reveal any short-term safety concerns (toxicity and adverse effects) after intravitreal bevacizumab. 4.The effect of intravitreal triamcinolone acetonide persisted longer than intravitreal bevacizumab. 5.The therapeutic effects of intravitreal triamcinolone acetonide revealed no significant differences compared with intravitreal bevacizumab in branch retinal vein occlusion.

<< Previous
Identifying Patients in Financial Need

Next >>
Predictors for visual field progression and the effects of...

Associations between chronic glycosylated haemoglobin (HbA1c) level and macular volume in diabetes patients without macular oedema
Acta Ophthalmologica, 11/13/09 Relevance Score: 68%

Improving intraocular lens power prediction in combined phacoemulsification and vitrectomy in eyes with macular oedema
Acta Ophthalmologica, 11/17/09 Relevance Score: 66%

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema
Cochrane Reviews, 10/20/09 Relevance Score: 66%

Diabetic macular oedema and visual loss: relationship to location, severity and duration
Acta Ophthalmologica, 10/12/09 Relevance Score: 65%

Vasoproliferative retinal tumours in a Swedish population
Acta Ophthalmologica, 11/06/09 Relevance Score: 64%